Main Newsletter
Mastery Series
Therapy Series
 

Letter From The Editor

Letter from the Editor, #760

This week there was some really interesting information about patients, hospitals, rewards, and penalties. Propublica Communications, a non-government watchdog of financial healthcare issues, reported that increasingly non-profit hospitals...


Editor's Note, DCMS #219

Our pharmacy was recently included in a large training program from Novo to educate pharmacists on how to use the new FlexTouch pen. This new pen eliminates the thumb throw that makes it hard for many patients to delver larger doses of insulin. One...


Editor's Note, SGLT-2 Inhibitor Special Edition, December 2014

Merry Christmas, Happy Chanukah, and Happy New Year! I was cleaning out some old diabetes slide presentations from 2007-2010 from my computer and I happened to open a few of them to make sure I wasn't missing any good slides before I...



Letter from the Editor, #759

This past Thursday I got to see just how good cyclists can be when they're in competition. I had qualified for the Florida Senior Games and was in Cape Coral to attempt to qualify for the nationals in the 60-64 age group. The first race was 20K...


Editor's Note, DCMS #218

In our main newsletter last week we had an item about the effects of TZD's on metabolism and...


Editor's Note, GLP-1 Analog Special Edition, December 2014

As we close out another year in diabetes care there is a lot to look back at. GLP-1 analogs are continuing to grow in


Editor's Note, Insulin Special Edition, December 2014

Last month I shared an event that occurred in the pharmacy concerning a 22-year-old man with type 1 diabetes who came...


Letter from the Editor, #758

It has been about five years since Dr. Steven Nissen started his public attack on the TZDs. His outspoken observations drove many prescribers away from using pioglitazone or rosiglitazone, and the FDA even agreed with his opinions, which drove the...


Editor's Note, DCMS #217

It appears that the weather this winter may turn out to be worse than last year's. Even here in sunny St. Petersburg, Fla., I had to pull out the winter gear for cycling. During these cold times patients often complain about their feet hurting more...


Letter from the Editor, #757

When Walmart first introduced their $4 generic drug program we thought that it would be an oddity for a month or two and then go away. Then everyone jumped on the bandwagon and soon these programs were so commonplace that our patients felt anything...


Editor's Note, DCMS #216

Every time we talk to a patient newly diagnosed with diabetes we talk about the kidneys, the feet, and the eyes, and what can happen if we let our glucose levels run rampant. We focus on this because the concept of microvascular complications has...


Letter from the Editor, #756

When the first gastric bypass was done, the incision was about 6-9 inches long. Then came lap band surgery for weight loss. We have gone from 4 incisions to one small incision over the past five years. We are always looking for less-invasive ways...


Editor's Note, DCMS #215

A little over five years ago, a small company came to market with a low-dose rapid-acting dopamine receptor agonist with a claim that it could reset metabolism endpoints in the neuroendocrine system. Soon as prescribers heard the word "dopamine,"...


Editor's Note, SGLT-2 Inhibitors Special Edition, November 2014

A couple of questions came up last week during a review of SGLT-2 inhibitors by my interns.  The first question had to do with what was happening with SGLT-1 receptors in the research, as one of the students had remembered that there are 8 or...


Letter from the Editor, #755

For the past two months our well-written fitness guru Dr. Sheri Colberg has been discussing the reasons why activity improves your brain health. This week


Editor's Note, DCMS #214

The prevailing statistics say that 74% of all diabetes patients have high lipids, 75% have hypertension, and that 56% of all diabetes patients have both conditions. If you take the time to read all of this week's clinical newsletter you will learn...


Editor's Desk, GLP-1 Agonist Special Edition, November 2014

If you have never considered using a GLP-1 analog with insulin then you need to read this month's update, and then think about how insulin and these analogs can be used together. While most of the the GLP-1's are indicated with insulin, we don't...


Letter from the Editor, #754

Last week, my daughter was out for a 100 mile bike ride and at mile 78 she was coming down a bridge on Madera Beach at about 27 mph when a car cut in front of her to make a right turn. She braked very hard, hit some gravel and glass and...


Editor's Note, DCMS #213

Every week we see patients who can't tolerate metformin, and we often have to chose a less effective but more expensive medication for their diabetes. We try decreasing the dose and then titrating back up, and even that does not work. For years,...


Editor's Note, Insulin Special Edition, November 2014

Last night I was in the pharmacy and a 22-year-old man came in with prescriptions for insulin, syringes, glucose meter, test strips and lancets. He had come by motorcycle and while he was waiting for his prescription he never took off his helmet or...


Letter from the Editor #753

Our good friend and Advisory Board member, Andrew Young, is one of the fittest type 1 patients I have ever met. He runs, cycles, surfs, does yoga, and is constantly working his body to improve his fitness especially for cardiovascular health. He...


Editor's Note, DCMS #212

Patients often have to deal with problems we never think of and that makes it hard for them to manage their diabetes. This becomes most important when our patients are insulin users, especially if they have tactile problems or arthritis or joint...


Letter from the Editor, #752

The diabetes drug arena is getting more crowded by the day as new classes of drugs like SGLT-2 inhibitors and


Editor's Note, GLP-1 Agonist Special Edition, October 2014

I was in a doctor's office last week and reached into a drawer to get a pen and, lo and behold, I came out with one of those old metal GLP-1 promotional pens. It was silver with orange yellow and blue-green strips, and felt really good in my...


Editor's Note, SGLT-2 Inhibitors Special Edition, October 2014

Sometimes it seems as if we don't talk about an organ or a problem until we have a medication to treat it. For years we didn't consider the kidney as a problem area for diabetes. It was not until we identified the SGLT-1 and -2 receptors that we...


Editor's Note, DCMS #211

Each week there seem to be articles, studies, and clinical treatises that draw a link between diabetes and cardiovascular disease. If you look through all these documents, the benchmark for measurement always seems to be A1c. However, if you were...


Letter from the Editor, #751

There is some interesting research going on at the University of Missouri about high protein breakfasts that actually delivers a profound message for a reason...


Editor's Note, Insulin Special Edition, October 2014

We have added five totally new classes of non-insulin medications for the treatment of diabetes and so sometimes the reasons to even try insulin make no sense to many of us. However, when we identify patients that have severe cases of...


Editor's Note, DCMS #210

This past weekend I was in Lexington, Kentucky to visit my father and sisters. While I was there, I saw a commercial for a heart institute and they mentioned that heart disease was the number one killer in America today. I would have to agree that...


Letter from the Editor, #750: ACO Update

Two years ago the Affordable Care Act brought about the beginning of ACO's (accountable care organizations). These organizations were created to bring quality of care into play for patients and to reward the best care providers with financial...


Editor's Note, DCMS #209

When we were kids, we used to play a game called Red Light/Green Light, and the goal was to sneak up on the "it" person without them catching your moves. In this week's Homerun Slides series, we bring you a way to use this game


Letter from the Editor, #749

This week we find that a lot of information is coming out the EASD meeting in Vienna, and much of it has to do with


Editor's Note, DCMS #208

The FDA works really hard these days to come up with new brand names that will lessen the chance of drug choice confusion. Often times we wonder how they can come up with these names and what meaning they have. With this in mind, this week's...


Letter from the Editor, #748

For the past 18 months we have been providing you with a monthly newsletter with special features focused on GLP-1 analogs. These newsletters have provided information...


Editor's Note, GLP-1 Agonists Special Editions, September 2014

There has been a lot going on with drugs in the GLP-1 agonist class over the past few months. First we added Tanzeum (albiglutide) as a once-a-week drug. Then the new Bydureon pen was introduced, and finally, Lilly got their once-weekly...


Editor's Note, DCMS #207

In 1969, the group Santana first recorded the song "Evil Ways" with these lines, "You've got to change your evil ways, baby ... You've got to change, baby, And every word that I say is true...." It seems that when it comes...


Letter from the Editor, #747:

This was a busy week in the GLP-1 arena. An FDA advisory panel last week overwhelmingly recommended approval of Novo Nordisk's latest weight-loss drug, Saxenda. This medication, which is liraglutide 3 mg, was recommended as an adjunct to diet and...


Editor's Note, DCMS #206

When Al Mann first said he was going to develop an inhaled insulin, many thought he was beating a dead horse after the collective experiences with Exubera. They forgot that Al had already built the most successful pump company of all times, and...


Editor's Note, SGLT-2 Inhibitor Special Edition, September 2014

As new medications for diabetes come to market there is always a question as to how well they will work when added to other medications. This month, we have a slide presentation from the ADA, outlining the rationale for mating DPP-4...


Letter from the Editor #746

This week we have an item about the increased use of gastric sleeve for weight reduction and the reversal of diabetes. This newer procedure is actually...



Navigate through our listing of Letter From The Editor articles here.
Next Last

581 Total articles for Letter From The Editor


Browse our other news categories below.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Looking for a particular Newsletter Issue? Click Here


Cast Your Vote
For your prediabetes patients who can't lower their blood glucose with lifestyle changes, do you prescribe GLP-1s or SGLT-2s?
CME/CE of the Week
Jeffrey A. Niezgoda, MD

Category: Wound Care
Credits: .75


Advertisement


Search Articles On Diabetes In Control